Biosensor Patent Landscape in 2026
Biosensor Patent Landscape in 2026
The biosensor patent field—spanning 5,421 patent families—is led by a concentrated tier of diagnostics and pharmaceutical incumbents, with F. Hoffmann-La Roche and its affiliated entities commanding the top positions. Annual filing volume peaked around 2018 and has since eased back, placing the field in a declining phase on a per-year basis, though substantial accumulated prior art in electrochemical and immunoassay sensing continues to shape freedom-to-operate considerations.
Roche-affiliated entities lead a concentrated but multi-tier competitive field
F. Hoffmann-La Roche & Co AG holds the top position with 1,910 patent records among the hundred largest filers, followed closely by Genentech Inc (1,613) and the Regents of the University of California (1,248). These three alone illustrate the breadth of the field: a Swiss diagnostics giant, a US biotech subsidiary, and a major research university all registering significant biosensor-adjacent portfolios.
The top five filers—Roche, Genentech, UC Regents, Koninklijke Philips, and Ascensia Diabetes Care—together account for 19% of the combined total of the hundred largest filers. This moderate concentration figure masks a steeper tier gap: the leader’s count is nearly double that of the fifth-ranked applicant, suggesting a genuine first-mover advantage at the top while the mid-tier remains contestable.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | F HOFFMANN LA ROCHE & CO AG | 1,910 | |
| 2 | Genentech Inc | 1,613 | |
| 3 | Regents of the University of California | 1,248 | |
| 4 | Koninklijke Philips NV | 1,239 | |
| 5 | Ascensia Diabetes Care Holdings AG | 975 | |
| 6 | ARKRAY Inc | 901 | |
| 7 | PHC Holdings Corporation | 852 | |
| 8 | Panasonic Holdings Corporation | 833 | |
| 9 | ZymoGenetics Inc | 701 | |
| 10 | Regeneron Pharmaceuticals Inc | 677 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | LifeScan Inc | 645 | |
| 12 | Illumina Inc | 643 | |
| 13 | French National Centre for Scientific Research (CNRS) | 564 | |
| 14 | Bristol Myers Squibb Co | 541 | |
| 15 | Fujifilm Corporation | 538 | |
| 16 | Abbott Diabetes Care Inc | 517 | |
| 17 | Bayer Healthcare LLC | 504 | |
| 18 | Roche Diabetes Care Inc | 469 | |
| 19 | Roche Diagnostics GmbH | 467 | |
| 20 | Millennium Pharmaceuticals Inc | 458 |
The Roche group’s dominance (with Roche Diabetes Care, Roche Diagnostics GmbH, and Roche Diagnostics Operations also appearing in the top 20) signals deep vertical integration across the glucose-monitoring and point-of-care diagnostics value chain. Challengers from electronics (Panasonic, Philips) and pharma (Bristol Myers Squibb, Regeneron) reflect how widely biosensor technology cuts across sectors, but none has yet closed the gap with the diagnostic-pure-play leaders.
Data for 2024–2025 reflect publication lag and substantially undercount activity initiated in those years; the apparent sharp drop in recent periods should not be read as a real-time measure of R&D momentum. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Annual volume has eased from its 2018 peak; electrochemical sensing dominates the technology mix
Two lenses—the annual filing trend and the IPC branch composition—together reveal a field whose core technology routes are mature but whose adjacent branches remain relatively underexplored. The trend chart identifies the activity cycle; the composition chart shows where accumulated prior art is densest.
Annual filing trend
Annual filings reached their highest observed level in 2018 (770 records) and have trended downward since, consistent with the field’s lifecycle classification as declining on a per-year basis. The 2024 and 2025 data points are substantially suppressed by publication lag and must not be interpreted as reflecting actual R&D output in those years. The 2020 dip may partly reflect pandemic-related examination delays rather than a genuine activity trough.
↗ Hover for values · click a bar to ask EurekaTechnology composition
G01N (Material analysis and testing) is overwhelmingly dominant, reflecting the field’s electrochemical and optical sensing core. C12Q (enzyme and DNA-based measurement) is the second largest branch, underscoring the importance of enzymatic glucose detection and molecular diagnostics. A61B (diagnosis and surgery), C12N (microorganisms and genetic engineering), and C07K (peptides and proteins) follow at roughly comparable shares, pointing to the integration of biosensors with therapeutic and genomic workflows. Lower-share branches such as G06F (digital data processing), G16H (healthcare informatics), and B81B (MEMS) represent adjacent areas where patent density is sparse relative to the technical opportunity.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Biological Sensor and a Method of the Production o…
The invention is related to the field of biotechnology, specifically to the investigation of biomolecular interactions and sensing of biomolecules using a surface plasmon resonance. The biological sensor and a method of its production based on the thin films of graphene, graphene oxide, or single-walled or multi-walled carbon nanotubes are described. The… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Subcutaneous glucose electrode | 2,642 |
| 2 | Process for producing an electrochemical biosensor | 2,246 |
| 3 | Interferant eliminating biosensor | 1,860 |
| 4 | Enzyme electrodes | 1,787 |
| 5 | Interferant eliminating biosensors | 1,738 |
| 6 | Biosensor and a process for preparation thereof | 1,597 |
| 7 | Signal processing for measurement of physiological… | 1,592 |
| 8 | Electrode and method for the detection of hydrogen… | 1,543 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for biosensor R&D investment decisions
Taken together, the lifecycle stage, concentration profile, co-filing network, and jurisdictional spread define a field where defensive positioning is critical and where incremental differentiation in adjacent branches may offer better returns than head-on entry into the electrochemical core.
Field is in a declining phase by annual volume
The lifecycle evidence classifies biosensors as Declining, with annual filings easing back from the 2018 peak. For an R&D team, this means the foundational electrochemical and immunoassay IP layers are dense and largely held by incumbents. New entrants should prioritize design-around strategies or focus on emerging sub-domains—such as MEMS integration or AI-assisted signal processing—where prior-art density is lower. Publication lag means 2024–2025 activity is still underrepresented and should be re-assessed as data matures.
Lifecycle: DecliningModerate overall share, steep top-tier gap
The top five filers hold 19% of the hundred largest filers’ combined total, a figure that reads as moderate concentration but conceals a significant gap between the leader (1,910 records) and the fifth-ranked applicant (975 records). The mid-tier—from ARKRAY through Panasonic—is relatively tightly bunched, suggesting that rank shifts in positions 6–10 are plausible with sustained filing activity. For a challenger, targeting specific application segments (e.g., continuous glucose monitoring or wearable biosensors) is more tractable than competing across the full breadth of the Roche portfolio.
Concentration: ModerateIntra-Roche co-filing dominates; academic partnerships are a secondary axis
The most active co-filing pair is F. Hoffmann-La Roche with Roche Diagnostics (172 joint records), reflecting coordinated portfolio management within the group. A second Roche pairing—with Roche Diabetes Care—adds 39 further joint records. Outside the Roche network, ARKRAY co-files with Ultimate Enzyme International (29 records), and Panasonic with ARKRAY (20 records), indicating supply-chain-driven collaboration in the glucose-strip segment. SRU Biosystems co-files with the University of Illinois (18 records) and the University of California (11 records), representing the most visible industry-academia axis. New entrants could exploit academic partnerships as a cost-efficient route to foundational IP in adjacent branches.
Collaboration: Intra-group dominantUS filing activity is primary; EPO and PCT coverage is substantial
The United States is the lead jurisdiction by a wide margin, with Europe (EPO) and WIPO (PCT) providing the next largest coverage layers. Canada and Australia also carry meaningful filing counts, consistent with the regulatory and commercial importance of those markets for in-vitro diagnostics. The relative sparsity of filings in Southeast Asia (Singapore, Philippines) and South Africa suggests that geographic white space exists in emerging-market jurisdictions, though commercial viability in those markets would need independent validation before filing resources are committed.
Geography: US-primaryGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| F. Hoffmann-La Roche Ltd | Roche Diagnostics GmbH | 172 |
| F. Hoffmann-La Roche Ltd | Roche Diabetes Care Inc | 39 |
| ARKRAY Inc | Ultimate Enzyme International Inc | 29 |
| Panasonic Corporation | ARKRAY Inc | 20 |
| SRU Biosystems Inc | Board of Trustees of the University of Illinois | 18 |
| SRU Biosystems Inc | Regents of the University of California | 11 |
| Roche Diagnostics GmbH | Roche Diagnostics Corporation | 11 |
| Panasonic Corporation | Sanyo Electric Co Ltd | 10 |
| F. Hoffmann-La Roche Ltd | Roche Diagnostics Operations Inc | 9 |
| Roche Diagnostics GmbH | Roche Diagnostics Operations Inc | 9 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Roche leads in electrochemical and enzymatic sensing; Genentech anchors the biotech-diagnostics axis
The top two ranked applicants together illustrate the dual character of the biosensor field: a dedicated diagnostics division (Roche) and a biotech entity whose biosensor-adjacent IP connects sensing to therapeutic development (Genentech). Their technology emphases and trajectory differ in ways that matter for competitive positioning.
F. Hoffmann-La Roche & Co AG
Ranked first with 1,910 patent records, Roche’s biosensor portfolio is concentrated in G01N 27 (electrochemical material analysis, 256 records), G01N 33 (immunoassay-based testing, 236 records), and C12Q 1 (enzyme/DNA-based measurement, 104 records)—a profile that maps directly to glucose strip and point-of-care diagnostics. Momentum data show only 1 recent filing attributed to this entity in the tracked window, flagged as a new-entrant signal, which likely reflects a consolidation of filings under affiliated entities (Roche Diabetes Care, Roche Diagnostics GmbH) rather than a genuine activity halt. The broader Roche group’s combined presence across the top 20 reinforces its structural dominance.
patent records: 1,910Illumina Inc
Ranked twelfth with 643 patent records, Illumina’s technology emphasis is distinctly different from the electrochemical leaders: its top focus areas are G01N 21 (optical/spectroscopic analysis, 134 records), B01L 3 (lab apparatus, 78 records), and H01L 27 (semiconductor devices, 71 records). This optical-semiconductor orientation positions Illumina in sequencing-adjacent biosensing rather than electrochemical glucose monitoring. Filing momentum shows a decline of 44% in the recent period versus the prior window, suggesting the company is consolidating rather than expanding its biosensor-specific footprint—a pattern consistent with its strategic pivot toward sequencing platform integration rather than standalone biosensor IP.
patent records: 643| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| F. Hoffmann-La Roche Ltd | 1 | ▲ new entrant |
| Regents of the University of California | 28 | ▼ -47% |
| ARKRAY Inc | 21 | ▲ +24% |
| Illumina Inc | 34 | ▼ -44% |
Under-served IPC branches adjacent to the biosensor core
The following branches appear in the biosensor corpus but at substantially lower patent-record density relative to the G01N core. They represent observations of relative sparsity; whether each constitutes a genuine R&D opportunity depends on technical fit and commercial context that must be assessed independently.
G06F / G16H · Digital data processing and healthcare informatics
With 310 records under G06F and 149 under G16H, software-layer biosensor IP—covering signal processing algorithms, cloud connectivity, and clinical decision support integrated with biosensor hardware—is sparse relative to the sensing-hardware core. As continuous glucose monitors and wearable biosensors proliferate, the value of robust, defensible software IP is increasing. Teams with expertise in embedded AI or clinical informatics could enter this space with relatively lower freedom-to-operate risk than in the electrochemical core. Entry paths include algorithm patents for noise filtering, anomaly detection, or multi-analyte fusion.
Search this in Eureka →B81B / B81C · MEMS and microstructural device integration
MEMS-integrated biosensors appear in only 103 records under B81B and 43 under B81C—a small fraction of the corpus. Miniaturized, implantable, or wearable biosensing platforms increasingly depend on MEMS fabrication techniques for electrode arrays, microfluidic channels, and on-chip reference electrodes. The technical opportunity is real: MEMS integration can improve sensitivity, reduce sample volumes, and enable multi-analyte detection. The sparsity here may reflect that dominant players are filing MEMS work under G01N rather than B81 classifications, so a freedom-to-operate analysis should cross-reference both branches before committing to an entry strategy.
Search this in Eureka →How leading applicants differ by IPC technology route
Strength of each leader across the main technology routes.
| Player | G01N 33 · Material analysis & testing | G01N 27 · Material analysis & testing | C12Q 1 · Measuring & testing involving enzymes/DNA | G01N 21 · Material analysis & testing | A61B 5 · Diagnosis & surgery |
|---|---|---|---|---|---|
| Panasonic Corporation | Strong · 328 | Strong · 362 | Strong · 317 | Absent | Emerging · 49 |
| F. Hoffmann-La Roche Ltd | Strong · 236 | Strong · 256 | Moderate · 104 | Absent | Absent |
| Bayer Healthcare LLC | Strong · 228 | Strong · 222 | Moderate · 100 | Absent | Emerging · 30 |
| Regents of the University of California | Strong · 198 | Strong · 107 | Strong · 104 | Moderate · 45 | Emerging · 31 |
| SRU Biosystems Inc | Strong · 242 | Absent | Absent | Strong · 236 | Absent |
| ARKRAY Inc | Strong · 121 | Strong · 209 | Moderate · 103 | Absent | Absent |
| Koninklijke Philips NV | Strong · 214 | Absent | Absent | Strong · 140 | Absent |
Frequently asked questions
The corpus covers 5,421 patent families. This total is the basis for lifecycle, trend, and technology-composition analysis; applicant rankings are derived separately at the patent-record level, where a family filing in multiple jurisdictions or under multiple IPC classes can contribute more than one record.
F. Hoffmann-La Roche & Co AG leads with 1,910 patent records among the hundred largest filers. Its portfolio is concentrated in electrochemical material analysis (G01N 27), immunoassay-based testing (G01N 33), and enzyme/DNA-based measurement (C12Q 1)—a profile aligned with glucose strip and point-of-care diagnostics.
The field is classified as Declining based on annual filing data. Volume peaked in 2018 and has eased back since. Note that 2024–2025 figures are substantially suppressed by publication lag and do not reflect real-time R&D output; those years should be re-evaluated as data matures.
The United States is the lead jurisdiction, followed by Europe (EPO) and WIPO (PCT). Canada and Australia also carry meaningful filing counts. Southeast Asian markets (Singapore, Philippines) and South Africa have comparatively sparse coverage.
The highest-cited work by title is ‘Subcutaneous glucose electrode’ (2,642 citations), followed by ‘Process for producing an electrochemical biosensor’ (2,246 citations) and ‘Interferant eliminating biosensor’ (1,860 citations). These foundational electrochemical and enzyme-electrode patents reflect the glucose-monitoring origins of the field’s most influential IP.
Relative sparsity exists in digital and software-layer branches (G06F with 310 records, G16H with 149 records) and in MEMS integration (B81B with 103 records, B81C with 43 records). These are observations of lower filing density adjacent to the dominant G01N core; technical fit and freedom-to-operate assessments are needed before treating them as confirmed R&D entry points.
Map your own biosensor patent landscape in minutes
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.